Qiagen’s stock jumped 16.6% in the most recent trading session, driven by unusually high volume. Approximately 1.4 million shares changed hands, compared with an average daily volume of 850,000 over the past month. This represents the largest one-day percentage gain for the diagnostics firm since November and underscores renewed investor interest in its molecular testing and life-science solutions offerings.

Analysts have revised their full-year earnings estimates upward by an average of 3.2% over the past four weeks, reflecting stronger than expected sales growth in the U.S. and Asia Pacific regions. Consensus projections now call for adjusted EPS of $2.38, up from $2.31 at the start of the quarter. However, forward guidance remains conservative, with management forecasting mid-single-digit revenue growth and flat to low-single-digit margin expansion, suggesting limited catalyst for another outsized rally in the near term.

According to Bloomberg News, Qiagen’s board has initiated a strategic review that includes potential sale scenarios, following approach interest from several private equity firms and larger diagnostics players. Sources indicate that the process is in early stages, with non-binding proposals expected by the end of the quarter. The review aims to maximize shareholder value by evaluating joint ventures, divestitures, and outright acquisition offers for the company’s molecular diagnostics division.